Knight Therapeutics Announces Relaunch of ORGOVYX in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX (relugolix) in Canada.

In June 2024, Knight and Sumitomo Pharma America Inc. (“SMPA”) announced that Knight and SMPA’s affiliates had entered into exclusive license and supply agreements to commercialize MYFEMBREE (relugolix/estradiol/norethindrone acetate), ORGOVYX (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products (the “Mature Products”, together with MYFEMBREE, ORGOVYX and vibegron, the “Products”).

ORGOVYX (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by Health Canada for the treatment of adult patients with advanced prostate cancer. ORGOVYX was approved in October 2023 and launched in March 2024. In February 2025, the pan-Canadian Pharmaceutical Alliance (“pCPA”) negotiations were concluded successfully and ORGOVYX has since received public listing in most provinces across Canada. ORGOVYX competes in the GnRH (Gonadotropin-releasing hormone) agonist and antagonist market for prostate cancer, which, based on IQVIA, is valued at over $200 million and has been growing at a five-year CAGR of 8%.

"ORGOVYX offers health care professionals a convenient oral alternative to rapidly suppress testosterone production for patients with prostate cancer. This new therapeutic option empowers clinicians to align treatment with each patient’s unique needs, helping optimize the best possible outcomes," said Samira Sakhia, President and CEO of Knight. “ORGOVYX is synergistic with our existing oncology portfolio with TRELSTAR and will allow Knight to leverage our existing infrastructure."

About ORGOVYX (relugolix)

ORGOVYX (relugolix 120mg tablets) is the first and only oral GnRH receptor antagonist approved by Health Canada for the treatment of adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the pituitary GnRH receptor, thereby reducing the release of the luteinizing and follicle-stimulating hormones, and consequently reducing the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer.¹ According to IQVIA, sales of ORGOVYX in Canada were approximately $1.2 million in 2024.